Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zimmer Biomet Holdings (ZBH – Research Report) and Antibe Therapeutics (ATBPF – Research Report).
Zimmer Biomet Holdings (ZBH)
In a report released today, Josh Jennings from TD Cowen maintained a Hold rating on Zimmer Biomet Holdings, with a price target of $143.00. The company’s shares closed last Wednesday at $121.84.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Zimmer Biomet Holdings with a $133.59 average price target, implying an 8.2% upside from current levels. In a report issued on February 8, Needham also maintained a Hold rating on the stock.
See today’s best-performing stocks on TipRanks >>
Antibe Therapeutics (ATBPF)
In a report released today, Stefan Quenneville from Echelon Wealth Partners maintained a Buy rating on Antibe Therapeutics, with a price target of C$2.00. The company’s shares closed last Wednesday at $0.68.
According to TipRanks.com, Quenneville is ranked #8229 out of 8716 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Antibe Therapeutics.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZBH:
- Zimmer Biomet signs Global Health Equity Network’s Zero Health Gaps Pledge
- Zimmer Biomet price target raised to $130 from $120 at Barclays
- Zimmer Biomet price target lowered to $140 from $147 at Deutsche Bank
- Zimmer Biomet price target raised to $132 from $119 at Wells Fargo
- Citi opens ‘positive catalyst watch’ on Zimmer Biomet into AAOS
